116 related articles for article (PubMed ID: 21612064)
1. [Analogues of amylin, alpha-glucosidase inhibitors and the digestive system in homeostasis regulation].
Rybka J
Vnitr Lek; 2011 Apr; 57(4):381-7. PubMed ID: 21612064
[TBL] [Abstract][Full Text] [Related]
2. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
3. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
[TBL] [Abstract][Full Text] [Related]
4. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
5. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
6. Optimizing diabetes treatment using an amylin analogue.
Edelman SV
Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
[TBL] [Abstract][Full Text] [Related]
7. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
8. Primer on pramlintide, an amylin analog.
Traina AN; Kane MP
Diabetes Educ; 2011; 37(3):426-31. PubMed ID: 21471470
[TBL] [Abstract][Full Text] [Related]
9. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of amylin and amylin deficiency.
Kruger DF; Gatcomb PM; Owen SK
Diabetes Educ; 1999; 25(3):389-97; quiz 398. PubMed ID: 10531859
[TBL] [Abstract][Full Text] [Related]
11. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
12. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
14. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
15. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
16. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
18. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
19. Alpha-glucosidase inhibitors in diabetes. Introduction.
Kruseman AC; Sels JP; Wolffenbuttel BH
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():1. PubMed ID: 8001619
[No Abstract] [Full Text] [Related]
20. Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
Grunberger G
J Diabetes; 2013 Jun; 5(2):110-7. PubMed ID: 23452312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
